Caixa and Inveready back Minoryx

Caixa Capital Risc invested in Minoryx through the €8m Caixa Capital Micro vehicle, which makes equity investments of €50,000. Inveready committed capital from Inveready Biotech II, which holds €15.5m.

The fresh funding will allow the firm to advance the development of drugs for three rare neurometabolic disorders and complete the preclinical studies required to start human clinical trials in 2015.

Company
Founded in 2011 and based in Barcelona, Minoryx is dedicated to the treatment of rare diseases, particularly neurometabolic diseases in children and adolescents.

The company uses a technological platform and proprietary biological screening technology to discover small molecule-based drugs that restore the functionality of enzymes that have become defective due to genetic mutations.

People
Sara Secall is investment director of the Inveready Biotech II fund. Carlos Trenchs is a director at Caixa Capital Risc.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain
• Caixa Capital Risc
• Inveready First Capital